Dose Formulation Analysis for Concentration and Homogeneity by PhDs at 20+ Year, FDA-Inspected Lab

It is the analytical proof that the animals received what the protocol says: the test article’s concentration, homogeneity and stability verified in the actual dosing preparation. Every GLP tox study rests on it, because if the dose was wrong, every downstream number, exposure, NOAEL, safety margin, inherits the error. Regulators require it precisely because nobody looks at it until it fails.

Because suspensions settle. A formulation that has stratified in the container doses the first animal differently from the last, and a single mid-container pull would never show it. Sampling across the container is how a homogeneity claim earns the word, and it is standard practice here rather than an add-on.

Three windows that map to how dosing really happens: stability at the storage condition, at room temperature during handling, and across the dosing period itself. A formulation stable in the freezer but degrading on the bench during a dosing session fails exactly where it matters; the arms are designed against your dosing schedule, not a generic template.

In your vehicle, always. Accuracy, precision, specificity, linearity and range are validated in the actual formulation you dose, because a method proven in a clean surrogate has proven nothing about a suspension full of excipients. Solutions, suspensions, emulsions, lipid nanoparticles, diet admixture and gavage preparations are all in scope.

Yes, and it is faster and cheaper than redeveloping. Send the method and its history; transfer and verification run here, with any gap named in writing before study commitment. The same applies in reverse if your program later consolidates elsewhere: methods documented here travel.

The one your test article needs, not the most expensive one available. HPLC-UV or fluorescence carries most formulation work; LC-MS enters where sensitivity or specificity genuinely demands it. Both sit in this building, so the recommendation is driven by the molecule rather than by what the lab happens to own.

Inside the window your study actually has. Formulation analysis is calendar-critical, results that arrive after dosing day are trivia, so turnaround is scoped against your dosing dates at the quote stage and the lab plans batches to the study, not the reverse.

Yes, routinely. Tox and safety CROs send formulation analysis here when it sits outside their own scope, with the reporting formatted to drop into their study file. Your study director gets a named contact and dated commitments, the same as any sponsor.

As long as the stability data says, and no longer. Hold time is established for your formulation in your vehicle during validation: at the storage condition, at room temperature, and across the dosing window your protocol actually uses. A generic answer here would be a guess; the stability arm replaces the guess with a number your study director can cite.